Pfizer Inc. announced a multi-year agreement with Gilead Sciences, Inc.
Gilead Sciences (GILD) has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc.
According to health authorities in South Korea, one third of seriously ill Covid-19 patients showed an improvement in their condition after being treated …
Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval to Gilead Sciences’ (GILD) remdesivir (“Veklury”) as the first treatment option for COVID-19. It …
Gilead Sciences (GILD) has announced encouraging additional data on remdesivir, the company’s investigational antiviral for the treatment of COVID-19. The data includes a …
Gilead Sciences Inc. (GILD) on Monday priced its experimental coronavirus drug candidate remdesivir at $2,340 per patient for a 5-day treatment in the …
India’s drug regulator granted Cipla Ltd. and Hetero Labs the approval to produce and sell a generic version of Gilead Sciences Inc.
Gilead Sciences (GILD) has now filed for conditional marketing authorization (CMA) of its antiviral medicine remdesivir for the treatment of COVID-19 with the European Medicines …
UK-based pharmaceutical company AstraZeneca Plc (AZN) is reportedly interested in a potential merger with rival drugmaker Gilead Sciences Inc. (GILD) in what would …
Shares in Gilead Sciences (GILD) traded down 3.4% on Monday after the company announced topline results from its Phase 3 SIMPLE trial in …
